296 PEGINTERFERON ALFA-2A (40KD) PLUS 800 OR 1000/1200 MG/DAY RBV IN G1 HIV-HCV-CO-INFECTED PATIENTS: EARLY RESPONSES TO TREATMENT AND PREDICTABILITY FOR SVR IN THE PARADIGM STUDY

✍ Scribed by M. Rodriguez-Torres; J. Slim; L. Bhatti; R.K. Sterling; T. Hassanein; B. Clotet; T. Branco; A. Bertasso; S. Stancic; M.S. Sulkowski

• Book ID: 117378382
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 52 KB
• Volume: 52
• Category: Article
• ISSN: 0168-8278
• DOI: 10.1016/s0168-8278(10)60298-x